NCT00347399

Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration

Effects of Intravitreal Injection of Bevacizumab in Combination With Verteporfin Photodynamic Therapy

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Asociación para Evitar la Ceguera en México · Academic / Other
• Sex: All
• Age: 55 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if of combination therapy of intravitreal bevacizumab 4 days after the application of photodynamic therapy could improve the visual outcomes of patients with neovascular age related macular degeneration.

Detailed description

The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious side effects have been reported with the use of this drug in oncologic patients. The intravitreal use has been reported in limited case reports and safety and efficacy should be determined. The purpose of this study is efficacy and safety of 2.5 mg intravitreal of bevacizumab for AMD 4 days after photodynamic therapy with verteporfin

Conditions

• Age Related Macular Degeneration

Interventions

Type	Name	Description
DRUG	bevacizumab intravitreal injection
PROCEDURE	verteporfin photodynamic therapy

Timeline

• Start date: 2006-03-01
• Primary completion: 2006-06-30
• Completion: 2007-06-30
• First posted: 2006-07-04
• Last updated: 2024-05-30

Locations

1 site across 1 country: Mexico